Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

750.22 -4.65 (-0.62%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
42 43 Next >
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Via Benzinga
Regeneron Pharmaceuticals Whale Trades For September 06
Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,900 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 20.17%. Currently, Regeneron... 
Via Benzinga
What Are Whales Doing With Regeneron Pharmaceuticals
A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange... 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain
The company reported more than 40% growth for Dupixent in the second quarter. 
Via Investor's Business Daily
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
Via Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
Via Benzinga
Amgen Moves to Dismiss Regeneron's Antitrust Case Regarding Cholesterol Drug
Via Benzinga
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
$100 Invested In This Stock 15 Years Ago Would Be Worth $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 19.74% on an annualized basis producing an average annual return of 26.98%. Currently, Regeneron... 
Via Benzinga
Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Via Benzinga
New Tensions Between The US And China Provoked Investors To Return To Safe-Haven Assets
Geopolitical tensions rose higher during the day after Chinese battery giant CATL said it would suspend plans to invest billions of dollars in a new battery plant in the United States because of House... 
Via Talk Markets
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regeneron Pharmaceutical Beats Second-Quarter Views But Logs No Covid Sales
Regeneron Pharmaceutical beat second-quarter estimates on Wednesday, leaning on Eylea as its Covid drug logged no sales. REGN stock rose. 
Via Investor's Business Daily
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022
Upgrades 
Via Benzinga
Meta Platforms To $250? Plus This Analyst Lowers Price Target On Microsoft
Morgan Stanley boosted the price target for American Express Company (NYSE: AXP) from $143 to $155. American Express shares rose 0.1% to $153.15 in pre-market trading. 
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Over the past 3 months, 10 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 20.57% on an annualized basis producing an average annual return of 27.06%. Currently, Regeneron... 
Via Benzinga
Air Pollution is a Global Heart and Lung Health Concern
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by... 
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.